Zambon’s acquisition creates position to ‘achieve advances’ for respiratory diseases

By Maggie Lynch contact

- Last updated on GMT

(Image: Getty/ Hero Images)
(Image: Getty/ Hero Images)

Related tags: Drug delivery, inhalation products, Orphan drug

Zambon acquires Breath Therapeutics for €140m to accelerate the commercialization of treatments for severe respiratory diseases.

The acquisition sees Germany-based Breath Therapeutics, a specialized biopharmaceutical company focused on developing inhalation therapies, becoming part of Zambon.

Breath Therapeutics’ drug candidate L-CsA-I, a liposomal formulation of cyclosporine A, is currently in two global Phase III trials, and will be added to Zambon’s drug portfolio through the agreement as well.

Zambon stated it expects the data from the Phase III trials of the drug in 2021 and will be commercialized by 2023, subject to approval.

The drug candidate is designed for inhaled administration for the treatment of bronchiolitis obliterans syndrome (BOS), a severe progressive lung disease that currently has no approved therapies. L-CsA-I has received an orphan drug designation for this treatment indication from the US Food and Drug Administration and European Medicines Agency.

BOS is a rapidly progressive disease that leads to respiratory failure and death within one to two years after diagnosis, according to Breath Therapeutics.

The disease commonly affects patients who have received lung or stem cell transplantation and is also associated with autoimmune diseases. Approximately 50% of the patient population that receives a complex transplant, such as a lung or stem cell, will develop BOS within five years after transplantation.

Related news

Show more

Related products

show more

Vaccine Innovation in the Era of COVID19

Vaccine Innovation in the Era of COVID19

Covance Patient Safety | 01-Oct-2020 | Sponsored Link

During this time of worldwide crisis, there is an increasing demand for the acceleration of a vaccination for COVID19. Regardless of the great recent advancements...

Single-Pass Tangential Flow Filtration

Single-Pass Tangential Flow Filtration

BioContinuum™ Platform - MilliporeSigma | 01-Aug-2020 | Application Note

Tangential flow filtration (TFF) is widely used in the biopharmaceutical industry for downstream processing applications. Typical TFF steps concentrate...

Flow Cytometry Services

Flow Cytometry Services

Q² Solutions | 01-Jun-2020 | Data Sheet

We are an established leader in flow cytometry services for clinical trials. Our technologies and solutions meet the growing global demand for enhanced...

Related suppliers

Follow us

Products

View more

Webinars